title: Opioid control of the in vitro release of cholecystokinin-like material from the rat substantia nigra.
abstract: Possible interactions between Met-enkephalin and cholecystokinin (CCK)-containing neurons in the rat substantia nigra were investigated by looking for the effects of various opioid receptor ligands and inhibitors of enkephalin-degrading enzymes on the K(+)-evoked overflow of CCK-like material (CCKLM) from substantia nigra slices. The delta-opioid agonists D-Pen2, D-Pen5-enkephalin (50 microM) and Tyr-D-Thr-Gly-Phe-Leu-Thr (DTLET; 3 microM) enhanced, whereas the mu-opioid agonists Tyr-D-Ala-Gly-MePhe-Gly-ol (DAGO; 10 microM) and MePhe3, D-Pro4-morphiceptin (PL 017; 10 microM) decreased, the K(+)-evoked release of CCKLM. By contrast, the kappa-opioid agonist U-50488 H (5 microM) was inactive. The stimulatory effect of DTLET could be prevented by the delta antagonist ICI-154129 (50 microM), but not by the mu antagonist naloxone (1 microM). Conversely, the latter drug, but not ICI-154129, prevented the inhibitory effect of DAGO and PL 017. A significant increase in CCKLM overflow was observed upon tissue superfusion with the peptidase inhibitors kelatorphan or bestatin plus thiorphan. This effect probably resulted from the stimulation of delta-opioid receptors by endogenous enkephalins protected from degradation, because it could be prevented by ICI-154129 (50 microM). Furthermore the peptidase inhibitors did not enhance CCKLM release further when delta-opioid receptors were stimulated directly by DTLET (3 microM). These data indicate that opioids acting on delta and mu receptors may exert an opposite influence, i.e., excitatory and inhibitory, respectively, on CCK-containing neurons in the rat substantia nigra.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: INSERM U288, Neurobiologie Cellulaire et Fonctionnelle, Faculté de Médecine Pitié-Salpêtrière, Paris, France.
authors.forename: J J
authors.initials: JJ
authors.lastname: Benoliel
authors.forename: A
authors.initials: A
authors.lastname: Mauborgne
authors.forename: S
authors.initials: S
authors.lastname: Bourgoin
authors.forename: J C
authors.initials: JC
authors.lastname: Legrand
authors.forename: M
authors.initials: M
authors.lastname: Hamon
authors.forename: F
authors.initials: F
authors.lastname: Cesselin
mesh_terms: D000818:Animals; D002118:Calcium / Q000494:pharmacology; D002766:Cholecystokinin / Q000378:metabolism*; D004723:Endorphins / Q000502:physiology*; D004744:Enkephalin, Methionine / Q000378:metabolism; D066298:In Vitro Techniques; D007930:Leucine / Q000031:analogs & derivatives / Q000494:pharmacology; D008024:Ligands; D008297:Male; D011188:Potassium / Q000494:pharmacology; D011863:Radioimmunoassay; D051381:Rats; D011919:Rats, Inbred Strains; D011957:Receptors, Opioid / Q000378:metabolism; D013378:Substantia Nigra / Q000378:metabolism*; D015244:Thiorphan / Q000494:pharmacology
chemical_list: D004723:Endorphins; D008024:Ligands; D011957:Receptors, Opioid; D004744:Enkephalin, Methionine; D002766:Cholecystokinin; D015244:Thiorphan; D007930:Leucine; C012211:ubenimex; D011188:Potassium; D002118:Calcium